Encouraged by these findings, we developed a peptide-based vaccine against survivin [14] and found this vaccine to induce T-cell responses in heavily pretreated melanoma and pancreatic cancer patients without significant toxicity [15, 16]. This evidence concerns the gene BIRC5 and melanoma.